Bioequivalence Analysis of Clindamycin Hydrochloride Capsules in Healthy Chinese Subjects Under Fasted and Fed Conditions
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1480 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Zhi Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trial Research Organization, Nancheng Hospital (Hepatobiliary Hospital), Dongguan, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Clindamycin, Fasting, Food-Drug Interactions. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Key Laboratory Project of Guangdong Medical Products Administration.
Abstract (Originalsprache)
Clindamycin is a lincosamide antibiotic for the treatment of staphylococcal, streptococcal, and anaerobic bacterial infections. We conducted a single‐center, single‐dose, 2‐preparation, 2‐period, 2‐sequence, randomized, open‐label, 2 × 2 crossover study to evaluate the pharmacokinetics (PKs) and safety of the test and reference clindamycin hydrochloride capsules in healthy Chinese subjects under both fasted and fed conditions. Forty‐eight subjects were enrolled in the study totally, with 24 subjects in each group. All subjects were asked to take a test or reference preparation, under either fasted or fed condition, and their blood samples were collected and assayed by a validated high‐performance liquid chromatography‐tandem mass spectrometry method. PK parameters including maximum plasma concentration, area under the plasma concentration‐time curve from time 0 to the last concentration, and area under the plasma concentration‐time curve from time 0 to infinity were estimated with noncompartmental model and analyzed. Results showed that the PK profiles of the 2 preparations were consistent and met the bioequivalence criteria. Food was identified as a factor that had an impact on clindamycin absorption. The safety of clindamycin hydrochloride capsules was satisfactory. This study proved that the 2 clindamycin hydrochloride capsules were bioequivalent in healthy Chinese subjects under both fasted and fed conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Trial Research Organization, Nancheng Hospital (Hepatobiliary Hospital), Dongguan, China.
- Clinical Research Center, KangHua Hospital, Dongguan, China.
- Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.
- Clinical Trial Management & Research Center, College of Pharmacy, Jinan University, Guangzhou, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Key Laboratory Project of Guangdong Medical Products Administration
- Guangdong Provincial Key Laboratory of Construction Foundation
- National Key Research and Development Program
- National Key Research and Development Program of China
Zitieren
APA
Wang, Z., Wen, H., Qian, X., Huang, M., Cheng, G., & Zhong, G. (2025). Bioequivalence Analysis of Clindamycin Hydrochloride Capsules in Healthy Chinese Subjects Under Fasted and Fed Conditions. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1480
Vancouver
Wang Z, Wen H, Qian X, Huang M, Cheng G, Zhong G. Bioequivalence Analysis of Clindamycin Hydrochloride Capsules in Healthy Chinese Subjects Under Fasted and Fed Conditions. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1480
BibTeX
@article{Wang2025,
author = {Wang, Zhi and Wen, Haitang and Qian, Xuebing and Huang, Min and Cheng, Guohua and Zhong, Guoping},
title = {Bioequivalence Analysis of Clindamycin Hydrochloride Capsules in Healthy Chinese Subjects Under Fasted and Fed Conditions},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1480}
}
EUVIMED